Highlights from SWOG

AYA Committee Report

The AYA Committee brought us more information from Dr. Mark Lewis about S1823. This trial is a "prospective observational cohort study to assess miRNA371 for outcome prediction in patients with early-stage germ cell tumors. If validated, it holds the promise to eliminate/reduce CT scans in the longitudinal follow-up of such GCT patients."

You can find more information about this trial [here](#).

Newly Published Study

During the meeting we found out S1417CD: Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer trial findings are now published. This was the first Cancer Care Delivery Trial ever under NCORP. SMC accrued 13 patients onto this study. Below is the link to view the reports and findings of this trial.

New SWOG Studies Opened During 2020

- **S1827**: "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)"
- **S1900C**: "A Phase II Study of Talazoparib plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (Lung-MAP Sub-Study)"
- **S1900B**: "A Phase II Study of LOXO292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)"
- **S1914**: "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC"
- **S1823**: "A Prospective Observational Cohort Study to Assess miRNA371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors"
The Cancer Letter

SHARPLESS LAYS OUT A SCENARIO FOR ACHIEVING 15% PAYLINE FOR RPCS
Budget increases in 2020 enabled NCI to boost funding for research and programs, pushing the payline up by two percentage points from last year’s level.

NCI WILL FORM AN AD HOC COMMITTEE TO REVIEW SCREENING TRIALS—THE FUTURE OF ECOG-ACRIN’S SLOWLY-ACCRUING TWIST IS IN QUESTION
NCI's cancer screening trials may be facing questions to the COVID-19 pandemic.

Meeting Updates

NCI NCORP Annual Meeting Part II

Tuesday, October 6, 2020
2:00–5:00 PM
You can find the full agenda and meeting times here

ECOG-ACRIN Fall Meeting
Tuesday, October 20 to Friday, October 23 (Virtual)
Registration for the ECOG-ACRIN Fall Meeting is now open!
See below the link to register

Registration to ECOG-ACRIN

You can find the full agenda and meeting times here

Wake Forest Annual Meeting
Thursday, October 29 – Friday, October 30

This virtual meeting is designed to familiarize attendees with current understanding of the etiology and treatment options for selected unmet cancer and treatment related symptoms/toxicities and CCDR challenges. It will also review the current and planned studies developed by the Wake Forest NCORP Research Base addressing these issues.

Registration is now open! To register for this meeting please use the link provided below.

<table>
<thead>
<tr>
<th>Grant Year 2</th>
<th>Date</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research Base</td>
<td>Date</td>
<td>Location</td>
</tr>
<tr>
<td>NCI NCORP Annual Meeting Part II</td>
<td>October 6, 2020</td>
<td>Virtual Meeting</td>
</tr>
<tr>
<td>ECOG-ACRIN Fall 2020</td>
<td>October 21-23, 2020</td>
<td>Virtual Meeting</td>
</tr>
<tr>
<td>Wake Forest Summer 2020</td>
<td>October 29-30, 2020</td>
<td>Virtual Meeting</td>
</tr>
<tr>
<td>Alliance Fall 2020</td>
<td>November 5-7, 2020</td>
<td>Virtual Meeting</td>
</tr>
<tr>
<td>NRG Oncology</td>
<td>January 28-30, 2021</td>
<td>New Orleans, LA</td>
</tr>
</tbody>
</table>

Accruals & Biospecimens–Special Entries
GY2 August 2020 Accruals
By Affiliate Site

NCI Assigned Performance Target Tracking
GY2 August YTD 2020

UC-NCORP Accruals
Accrual Goal

8
Treatment
10
Cancer Control
30
TMIST

160% of goal!

5
Treatment
5
Cancer Control
20
TMIST
30

0
10
20
30
40
50
60
CCDR Protocols Opening Soon

WF 1805CD HN–STAR: Implementation and Effectiveness Trial of HN–Star
- SMC, AnMed, and BSSF plan to open this trial

URCC 18004CD: Understanding the Impact of Drug Shortages On Oncology Care
- Please discuss with Melyssa if plan to open
- First training: is Wed Oct 7, 2020 1:00-2:30 pm EST (please note the time zone)

URCC 18110CD: Implementing Palliative Care: Learning Collaborative vs. Technical Assistance
- URCC is preparing to open site registration for Cohort 1 shortly
- If your site is interested in participating in Cohort 1 and has not yet completed a Practice Cluster Interest Form, please fill one out at this link and/or email urcc_18110@urmc.rochester.edu for more information-let Melyssa know
- If your site has already completed a Practice Cluster Interest Form and confirmed your participation for Cohort 1, please expect additional emails regarding the registration process soon.

We will discuss all upcoming and current CCDR trials on the Coordinator Call this Thursday October 1st
Hope to see you there!
Q.A. with Kelsey

Data Timeliness Tips:
- Utilize the CTSU Data Quality Portal (DQP) for an overview of Queries/Forms due for your site
- Check the DQP weekly to identify any new alerts of Queries/Forms due
- Strive for < 15 days for all query responses and form submissions

Audit Update:
S1418 (BSSF Only) – October 20, 2020

New Trials Available to Open

- **EA8185**: Phase 2 Study of Bladder-Sparing ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder CancEr (INSPIRE)
- **EA6192**: A Phase II Study of Biomarker Driven Early Discontinuation of Anti–PD–1 Therapy in Patients with Advanced Melanoma (PET–Stop)
- **A091902**: A Multicenter Phase II Trial of Paclitaxel with and Without Nivolumab in Taxane Naïve, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects with Angiosarcoma
- **NRG–HN007**: An Open-Label, Phase III Study of Platinum–Gemcitabine with or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Published Studies

- **URCC-14040 (YOCAS)**

All About AYA

AYA August Accruals

- 4 patients accrued
Dr. Crosswell leads a monthly AYA Molecular Tumor Board. During the September meeting, 4 AYA cases were presented to 39 participants representing the 10 institutions below.

- BSSF
- Duke
- MD Anderson
- Cook Children’s
- SRHS
- Novant
- OHSU
- DuPont
- UNC
- Nemours
- Moffitt

Smiling Faces

Do you have any staff you would like highlighted in The Connector? Please submit it by the 10th of the month to Alaina: akennedy@srhs.com

Click here to visit our website

Administrator
Kamara Mertz-Rivera
Email: UpstateNCORP@srhs.com
Phone: 864-560-6104

Regulatory
Heather Farmer
Email: UpstateNCORPRegulatory@srhs.com
Phone: 864-560-1060

Quality Assurance
Kelsey Bridges, MSHS
Email: UpstateNCORPQA@srhs.com
Phone: 864-560-1961

CCDR Coordinator